The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype

Stopped The scientific director decided to terminate: low priority study with slow accrual

Conditions

• Schizophrenia
• Memory Disorders
• Cognition Disorders

Interventions

• DRUG: Atomoxetine
• PROCEDURE: Functional magnetic resonance imaging
• PROCEDURE: Neuropsychological Testing
• DRUG: Placebo

Sponsor

National Institute of Mental Health (NIMH)